<DOC>
	<DOCNO>NCT02158533</DOCNO>
	<brief_summary>This study evaluate efficacy safety ALKS 5461 .</brief_summary>
	<brief_title>A Study ALKS 5461 Treatment Major Depressive Disorder ( MDD ) - FORWARD-4 Study</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Have Body Mass Index ( BMI ) 18.0 40.0 kg/m2 , inclusive Agree use acceptable method contraception duration study Have Major Depressive Disorder ( MDD ) primary diagnosis Have 2 inadequate response antidepressant therapy ( ADT ) current Major Depressive Episode ( MDE ) Additional criterion may apply Have current primary AxisI disorder MDD Have use opioid agonist ( eg , codeine , oxycodone , tramadol , morphine ) opioid antagonist ( eg , naloxone , naltrexone ) within 14 day Have receive electroconvulsive therapy treatment within last 2 year receive one course electroconvulsive treatment lifetime Have attempt suicide within past 2 year Have positive test drug abuse Are pregnant , plan become pregnant , breastfeed Have history intolerance , allergy , hypersensitivity buprenorphine opioid antagonist ( eg , naltrexone , naloxone ) Have significant blood loss blood donation within 60 day Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Alkermes</keyword>
	<keyword>ALKS 5461</keyword>
	<keyword>Samidorphan</keyword>
</DOC>